{"title":"Markov State Models in Drug Design","authors":"B. Keller, Stevan Aleksić, L. Donati","doi":"10.1002/9783527806836.CH4","DOIUrl":null,"url":null,"abstract":"Starting from the lock-and-key model [1], models of ligand–target binding have been extended to acknowledge the role of conformational flexibility. In current models, the targets are assumed to fluctuate between several different confor- mations. In the conformational selection model [2], one of these conformations is the active state, i.e. the conformation which is assumed in complex with the ligand. e ligand then “selects” this conformation from the ensemble and stabi- lizes it by forming a complex. By contrast, in the induced-fit model [3], the active conformation is not sampled by the apo-target. Instead, the receptor and the lig- and form an unspecific encounter complex. is weak complex then triggers a conformational rearrangement in the receptor, which leads to the fully formed complex. While examples of mechanisms have been found [4–7], most binding processes fall somewhere in between these two extremes. \n \n e conformational selection and the induced-fit model neglect the confor- mational dynamics of the ligand, which is justified if the ligand is either rigid or its dynamics is fast compared to the dynamics of the target. However, this is not always a valid assumption. In particular, peptides and peptidomimetics exhibit a complex and often slow conformational dynamics. It is increasingly recognized that the flexibility of the target and the ligand and their mutual inter- action are crucial factors in the ligand-binding process. us, to systematically vary the thermodynamic and kinetic properties of a drug molecule, not only bind- ing affinities but also dynamics need to be taken into account. \n \nExperimentally, it is difficult to characterize the full conformational ensem- ble and its dynamics. However, an increase in computer power combined with improved algorithms has rendered molecular dynamics (MD) simulations as use- ful tools in structure-based drug design [8]. With progress in distributed com- puting [9], special purpose computers [10], and graphics processing unit (GPU) devices [11], trajectories of several tens in microseconds are now accessible on a routine basis. \n \nA visual inspection of these trajectories is sometimes not feasible, due to the shear size of the data set, and almost always unrewarding, because it does not yield a quantitative description of the system.1 While statistical analyses of the trajectory for the stationary properties of the system have been used routinely for decades, methods which yield a model of the dynamics have matured only recently. Markov State Models (MSMs) [12–17], in which the dynamics is approx- imated as a Markovian jump process between distinct microstates, are the most widely used dynamic models. MSMs have been used to improve ensemble dock- ing, to optimize a specific conformation in a ligand, to identify cryptic allosteric sites, and to characterize ligand-binding processes as well as inactive-to-active transitions in signaling proteins. We do not aim at a comprehensive survey of the literature on this subject, nor do we focus on specific results. Our goal is to explain the different ways in which MSMs can be helpful in structure-based design.","PeriodicalId":427626,"journal":{"name":"Biomolecular Simulations in Structure-Based Drug Discovery","volume":"172 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecular Simulations in Structure-Based Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/9783527806836.CH4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Starting from the lock-and-key model [1], models of ligand–target binding have been extended to acknowledge the role of conformational flexibility. In current models, the targets are assumed to fluctuate between several different confor- mations. In the conformational selection model [2], one of these conformations is the active state, i.e. the conformation which is assumed in complex with the ligand. e ligand then “selects” this conformation from the ensemble and stabi- lizes it by forming a complex. By contrast, in the induced-fit model [3], the active conformation is not sampled by the apo-target. Instead, the receptor and the lig- and form an unspecific encounter complex. is weak complex then triggers a conformational rearrangement in the receptor, which leads to the fully formed complex. While examples of mechanisms have been found [4–7], most binding processes fall somewhere in between these two extremes.
e conformational selection and the induced-fit model neglect the confor- mational dynamics of the ligand, which is justified if the ligand is either rigid or its dynamics is fast compared to the dynamics of the target. However, this is not always a valid assumption. In particular, peptides and peptidomimetics exhibit a complex and often slow conformational dynamics. It is increasingly recognized that the flexibility of the target and the ligand and their mutual inter- action are crucial factors in the ligand-binding process. us, to systematically vary the thermodynamic and kinetic properties of a drug molecule, not only bind- ing affinities but also dynamics need to be taken into account.
Experimentally, it is difficult to characterize the full conformational ensem- ble and its dynamics. However, an increase in computer power combined with improved algorithms has rendered molecular dynamics (MD) simulations as use- ful tools in structure-based drug design [8]. With progress in distributed com- puting [9], special purpose computers [10], and graphics processing unit (GPU) devices [11], trajectories of several tens in microseconds are now accessible on a routine basis.
A visual inspection of these trajectories is sometimes not feasible, due to the shear size of the data set, and almost always unrewarding, because it does not yield a quantitative description of the system.1 While statistical analyses of the trajectory for the stationary properties of the system have been used routinely for decades, methods which yield a model of the dynamics have matured only recently. Markov State Models (MSMs) [12–17], in which the dynamics is approx- imated as a Markovian jump process between distinct microstates, are the most widely used dynamic models. MSMs have been used to improve ensemble dock- ing, to optimize a specific conformation in a ligand, to identify cryptic allosteric sites, and to characterize ligand-binding processes as well as inactive-to-active transitions in signaling proteins. We do not aim at a comprehensive survey of the literature on this subject, nor do we focus on specific results. Our goal is to explain the different ways in which MSMs can be helpful in structure-based design.
从lock-and-key模型[1]开始,配体与靶标结合的模型已经扩展到承认构象柔韧性的作用。在目前的模型中,假设目标在几个不同的结构之间波动。在构象选择模型[2]中,其中一种构象是活性态,即与配体配合时假设的构象。然后E配体从整体中“选择”这种构象,并通过形成络合物来稳定它。相比之下,在诱导拟合模型[3]中,主动构象不被载脂蛋白靶采样。相反,受体和光-和形成一个非特异性相遇复合物。弱复合物随后触发受体的构象重排,从而形成完全形成的复合物。虽然已经发现了一些机制的例子[4-7],但大多数结合过程介于这两个极端之间。E构象选择和诱导拟合模型忽略了配体的构象动力学,如果配体是刚性的或其动力学比靶的动力学快,这是合理的。然而,这并不总是一个有效的假设。特别是,肽和肽拟物表现出复杂且通常缓慢的构象动力学。人们越来越认识到靶体和配体的灵活性及其相互作用是配体结合过程中的关键因素。因此,要系统地改变药物分子的热力学和动力学性质,不仅要考虑结合亲和性,还要考虑动力学。在实验上,很难描述完整的构象场及其动力学。然而,随着计算机能力的提高和算法的改进,分子动力学(MD)模拟已经成为基于结构的药物设计的有用工具[8]。随着分布式计算[9]、专用计算机[10]和图形处理单元(GPU)设备[11]的进步,几十微秒的轨迹现在可以在日常基础上访问。由于数据集的剪切大小,对这些轨迹的目视检查有时是不可行的,而且几乎总是没有回报的,因为它不能产生系统的定量描述虽然对系统平稳特性的轨迹进行统计分析已经常规使用了几十年,但产生动力学模型的方法直到最近才成熟。马尔可夫状态模型(Markov State Models, msm)[12-17]是应用最广泛的动态模型,其中动力学近似为不同微观状态之间的马尔可夫跳跃过程。msm已被用于改善整体对接,优化配体中的特定构象,识别隐变构位点,表征配体结合过程以及信号蛋白的非活性到活性转变。我们的目的不在于对这一主题的文献进行全面调查,也不着眼于具体的结果。我们的目标是解释msm在基于结构的设计中发挥作用的不同方式。